Option chain shows key data for Abattis Bioceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Abattis Bioceuticals.

Abattis Bioceuticals (OTC:ATTBF) Stock, Option Chain

Abattis Bioceuticals Corp is a Canadian life science and biotechnology company focuses on aggregating, integrating and investing in agricultural technologies and biotechnology services for the legal cannabis industry. It is primarily engaged in producing, licensing and marketing proprietary ingredients and formulas for use in the biopharma, nutraceutical, cosmetic and animal nutrition markets. The company is also engaged in growing, extraction, testing, propagation and online distribution.

Cannabis

News

Markets

Movers

Trading Ideas

AGEEF

ATTBF

CBIS

CANNABIS WHEATON INCOME by Cannabis Wheaton Income Corp.

CBWTF

CURALEAF HLDGS INC by Curaleaf Hldgs Inc.

CURLF

FUTURE FARM TECHNOLOGIES by Future Farm Technologies Inc.

FFRMF

GLDFF

GRWG

IMLFF

IVITF

KALYTERA THERAPEUTICS ORD by Kalytera Therapeutics Inc.

KALTF

KHIRON LIFE SCIENCES CORP by Khiron Life Sciences Corp.

KHRNF

KSHB

MRMD

NABIF

NTEC

Cannabis Gainers And Losers From September 25, 2019

After-Hours Center

ACCA

AUSAF

CBDY

CNBX

CRON

CTST

DYMEF

GBHPF

GNLN

ITHUF

YCBD

BLEVF

Cannabis Gainers And Losers From September 19, 2019

CRLBF

CWBHF

ELLXF

EVIO

FSDDF

NDVAF

ORHOF

TETRA BIO-PHARMA INC ORD by Tetra Bio-Pharma Inc.

TBPMF

XXII

Cannabis Stock Gainers And Losers From September 12, 2019

ABATTIS BIOCEUTICALS ORD by Abattis Bioceuticals Corp.

Abattis Bioceuticals Corp

BTCM

BIT Mining Receives NYSE Letter That It Regained Compliance With Quantitative Continued Listing Standards

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.

Price Target

Reiteration

Analyst Ratings

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

Barclays analyst David Anderson downgrades Halliburton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HAL#NYSE">HAL</a>) from Overweight to Equal-Weight and lowers the price target from $43 to $33.

Downgrades

Barclays Downgrades Halliburton to Equal-Weight, Lowers Price Target to $33

Under the agreement, Hansoh Pharma has granted Merck an exclusive global license to develop, manufacture and commercialize HS-10535. Hansoh Pharma will receive an upfront payment of $112 million and is eligible to receive up to $1.9 billion in milestone payments associated with the development, regulatory approval and commercialization of the candidate, as well as royalties on sales.
Hansoh Pharma may co-promote or solely commercialize HS-10535 in China subject to certain conditions. Merck will record a pre-tax charge of $112 million, or $0.04 per share, to be included in GAAP and non-GAAP results in the fourth quarter of 2024.

Merck, Hansoh Pharma Enter Exclusive Global License Agreement For HS-10535, An Investigational Preclinical Oral Small Molecule GLP-1 Receptor Agonist; Hansoh To Receive An Upfront Payment Of $112M And Up To $1.9B In Milestones

Needham analyst Laura Martin reiterates Taboola.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBLA#NASDAQ">TBLA</a>) with a Buy and maintains $5 price target.

TBLA

Needham Reiterates Buy on Taboola.com, Maintains $5 Price Target

JP Morgan analyst Cory Carpenter maintains Take-Two Interactive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTWO#NASDAQ">TTWO</a>) with a Overweight and raises the price target from $195 to $225.

TTWO

JP Morgan Maintains Overweight on Take-Two Interactive, Raises Price Target to $225

HC Wainwright &amp; Co. analyst Joseph Pantginis reiterates PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) with a Buy and maintains $21 price target.

PDSB

HC Wainwright & Co. Reiterates Buy on PDS Biotechnology, Maintains $21 Price Target

JP Morgan analyst David Karnovsky downgrades PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) from Neutral to Underweight.

MYPS

JP Morgan Downgrades PLAYSTUDIOS to Underweight

Needham analyst Scott Berg reiterates Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) with a Buy and maintains $375 price target.

Needham Reiterates Buy on Salesforce, Maintains $375 Price Target

JP Morgan analyst Doug Anmuth downgrades Angi (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANGI#NASDAQ">ANGI</a>) from Overweight to Neutral.

ANGI

JP Morgan Downgrades Angi to Neutral

UMC will purchase more than 30 billion kilowatt-hours of power from Fengmiao I over least 30 years.
&nbsp;This agreement will help UMC achieve its goal of 50% renewable energy use by 2030 as part of the company's roadmap to net zero emissions and 100% renewable energy by 2050.

United Microelectronics Inks 30-Year, 30B kWh Offshore Wind Power Agreement  With Fengmiao I

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth reiterates ALX Oncology Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALXO#NASDAQ">ALXO</a>) with a Buy and maintains $25 price target.

ALXO

HC Wainwright & Co. Reiterates Buy on ALX Oncology Holdings, Maintains $25 Price Target

JP Morgan analyst Cory Carpenter downgrades Getty Images Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GETY#NYSE">GETY</a>) from Neutral to Underweight.

GETY

JP Morgan Downgrades Getty Images Holdings to Underweight

The engagement with an EU-based GMP manufacturing facility enables timely production and preparation for clinical trial. The EU-based GMP manufacturer has large-scale commercial production capabilities, to support Polyrizon in future commercialization efforts

PLRZ

Polyrizon Secures GMP Manufacturing Partnership With Eurofins CDMO Amatsiaquitaine, Advancing Toward PL-14 Allergy Blocker Clinical Trial In 2025

CMPS

Compass Pathways Common Stock To Be Added To The Nasdaq Biotechnology Index

JP Morgan analyst Cory Carpenter upgrades Xometry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XMTR#NASDAQ">XMTR</a>) from Neutral to Overweight and raises the price target from $25 to $45.

Upgrades

XMTR

JP Morgan Upgrades Xometry to Overweight, Raises Price Target to $45

JP Morgan analyst Cory Carpenter downgrades Match Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTCH#NASDAQ">MTCH</a>) from Overweight to Neutral and lowers the price target from $40 to $33.

MTCH

JP Morgan Downgrades Match Group to Neutral, Lowers Price Target to $33

Jefferies analyst Andrew Tsai initiates coverage on Rocket Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RCKT#NASDAQ">RCKT</a>) with a Buy rating and announces Price Target of $29.

Initiation

RCKT

Jefferies Initiates Coverage On Rocket Pharmaceuticals with Buy Rating, Announces Price Target of $29

U.S. stock futures climbed on Wednesday in premarket hours as Wall Street awaits the Federal Reserve&#8217;s final interest rate decision for 2024 and its monetary policy forecasts for 2025.
On Tuesday, the Dow Jones index fell for the <a href="https://www.benzinga.com/news/earnings/24/12/42546507/dow-records-longest-losing-streak-since-1978-nvidia-declines-fear-greed-index-in-neutral-zone">ninth session in a row</a> to record its longest losing streak since 1978.
The 10-year and two-year Treasury notes yielded 4.40% and 4.25%, respectively. The Federal Open Market Committee will announce its decision later in the day after a two-day meeting.
It is widely expected to announce another interest rate reduction at the conclusion of their meeting on Wednesday. Expectations of a 25 basis point rate cut rose to 95.4%, from 58.7% a month ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
If the Fed cuts rates, it would be the third consecutive cut, bringing the federal funds rate down from its current level of 4.50% to 4.75%. Following the meeting, Chairman Jerome Powell&#8217;s remarks will be closely scrutinized by market participants.
Investors will receive another critical economic data point on Friday with the release of the November personal consumption expenditures (PCE) inflation index. This release follows other inflation indicators that suggest price increases accelerated in November.
Prior to that, GDP revisions on Thursday will reveal whether the economy maintained the previously estimated 2.8% growth rate for the third quarter.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>0.24%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>0.28%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.24%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.49%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Wednesday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.25% to $605.80 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) rose 0.24% to $537.09, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
The <a href="https://www.benzinga.com/news/earnings/24/12/42546507/dow-records-longest-losing-streak-since-1978-nvidia-declines-fear-greed-index-in-neutral-zone">Dow Jones Industrial Average </a>extended its losing streak to nine consecutive sessions on Tuesday, its longest downturn since 1978. This negative trend weighed on the broader U.S. stock market.
While Tesla shares rallied after a positive analyst upgrade, Nvidia experienced a slight decline.
On the economic front, U.S. retail sales exceeded expectations in November, suggesting increased consumer spending. However, industrial production contracted, signaling a slowdown in manufacturing activity.
The S&amp;P 500 saw a broad-based decline, with industrials, energy, and financials leading the losses. Consumer discretionary stocks, on the other hand, bucked the trend and closed higher.
At the close of trading, the Dow Jones Industrial Average had fallen by approximately 268 points to 43,449.90. The S&amp;P 500 and Nasdaq Composite also ended the day lower, declining by 0.39% and 0.32%, respectively.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.32%</td>
<td>20,109.06</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.39%</td>
<td>6,050.61</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.61%</td>
<td>43,449.90</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-1.18%</td>
<td>2,334.08</td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
The Dow Jones Industrial Average index last saw a nine-day fall for the first time since February 1978, according to FactSet data. However, the index has seen steeper crashes in a single day as compared to the cumulative erosion it has witnessed over these nine days.
Dow Jones has fallen nearly 3.47% to 43,449.90 points over the last nine days since Dec. 4, when it was at 45,014.04 points.
&#8220;Since 1900, I see 267 times it lost more than 3.47% in a single day,&#8221; said Ryan Detrick, chief market strategist at Carson Research.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The Dow is down 3.47% the past 9 days (and lower all 9 of them). Since 1900, I see 267 times it lost more than 3.47% in a single day.
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1869205905780388184?ref_src=twsrc%5Etfw">December 18, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to BlackRock, the global economy is undergoing a transformation that could keep shifting the long-term economic trend. They suggest that investors should shift to distinct drivers of risk and return.
&#8220;That creates a wide range of potential outcomes and a need to use scenarios to guide portfolio construction, we think. Government bonds have become a less reliable cushion against risk asset selloffs in this new regime. So investors should consider new diversifiers like gold and bitcoin – not to replace bonds, but to get exposure to distinct drivers of risk and return.&#8221;
&#8220;We see the AI buildout and adoption creating opportunities across sectors,&#8221; BlackRock&#8217;s note added.
&#8220;Overall, with so much uncertainty around tariffs and inflation, bond market volatility is unlikely to fade anytime soon,&#8221; said JPMorgan in their note.
&#8220;The week's economic data releases appeared to be enough for markets to solidify expectations for a rate cut at the upcoming Federal Reserve meeting,&#8221; said T Rowe Price in their weekly note.
See Also: <a href="https://www.benzinga.com/money/how-to-trade-futures" target="_blank" rel="noreferrer noopener">How To Trade Futures</a>
Upcoming Economic Data
Important data is slated to be released this week that will help investors determine the future course of action.
<ul>
<li>On Wednesday, housing starts, and building permit data for November will be announced at 8:30 a.m., ET.</li>
<li>The FOMC&#8217;s interest rate decision will be announced at 2:00 p.m., ET, and the Fed Chair Jerome Powell&#8217;s press conference will begin at 2:30 p.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Parazero Technologies Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRZO#NASDAQ">PRZO</a>) was up 71.24% in premarket trading after it regained Nasdaq compliance.</li>
<li>Nukkleus Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NUKK#NASDAQ">NUKK</a>) gained 45.37% after the company announced it acquired a 51% controlling stake in Star 26 Capital.</li>
<li>Corvus Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRVS#NASDAQ">CRVS</a>) rose 17.73% in premarket after it said that it would report interim data from its Phase 1 clinical trial evaluating Soquelitinib in patients with moderate to severe atopic dermatitis, on Dec. 18.</li>
<li>Applied DNA Sciences, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APDN#NASDAQ">APDN</a>) fell 13.04% in pre-market trading after reporting weak quarterly sales.</li>
<li>Quantum Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QUBT#NASDAQ">QUBT</a>) was up 13.28% after it received a NASA contract doe Goddard Space Flight Center to use its entropy quantum optimization machine to help the space agency&#8217;s imaging.</li>
<li>Investors are awaiting earnings results from General Mills, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GIS#NYSE">GIS</a>), Jabil Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JBL#NYSE">JBL</a>, )) and Micron Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MU#NASDAQ">MU</a>) today.</li>
</ul>
Commodities, Bonds And Global Equity Markets:
Crude oil futures were lower in the early New York session by 0.03% to hover around $70.08 per barrel.
The gold spot index rose by 0.08% to $2,664.21 per ounce. The dollar index was up 0.04% to 106.997 level.
Asian markets were mixed on Wednesday, as Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300, and South Korea&#8217;s Kospi index advanced. Whereas, Japan&#8217;s Nikkei 225, India&#8217;s S&amp;P BSE Sensex, and Australia&#8217;s ASX 200 index declined. Most European markets advanced.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/market-summary/24/12/42548385/fund-managers-increase-allocation-to-banking-and-insurance-stocks-in-december-here-are-the-best-performing-financial-stocks-in-2024">Fund Managers Increase Allocation To Banking And Insurance Stocks In December: Here Are The Best Performing Financial Stocks In 2024</a></li>
</ul>
Photo courtesy: Wikimedia

Equities

Futures

Previews

Economics

Federal Reserve

Pre-Market Outlook

APDN

CRVS

NUKK

PRZO

QUBT

US Stocks To Open Higher As Rate Cut Expectations Surge: All Eyes On Dow Jones To Break Its 9-Day Losing Streak

HC Wainwright &amp; Co. analyst Swayampakula Ramakanth maintains electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) with a Buy and raises the price target from $22 to $25.

Comments

Abattis Bioceuticals

Abattis Bioceuticals (ATTBF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga